A Phase 1/2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Lupus Nephritis (KYSA-3)
KYV101-003
Phase 2 other active
Quick answer
A Phase 1/2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Lupus Nephritis (KYSA-3) for Lupus Nephritis is a Phase 2 program (other) at Kyverna Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Kyverna Therapeutics
- Indication
- Lupus Nephritis
- Phase
- Phase 2
- Modality
- other
- Status
- active